As of the 24th of March 2022, the patent secures C2Cs technological concept for industrial production, upscaling, and distribution of ASC products in Australia (Patent number: 2016342387).
The patent “STEM CELL THERAPY BASED ON ADIPOSE-DERIVED STEM CELLS” has previously been granted in Europe (19 European PCT countries) year 2020: Publication number EP3365432B1. Priority: October 2016.
Applications are still pending in Canada, China, Hong Kong, Japan, The Republic of Korea and in USA.
We look forward to further strengthening of our intellectual property.